Clovis Oncology（CLVS.Q）株式概要
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. 詳細
CLVS.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Clovis Oncology, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.015 |
| 52週高値 | US$2.87 |
| 52週安値 | US$0.01 |
| ベータ | 0.66 |
| 1ヶ月の変化 | -40.00% |
| 3ヶ月変化 | -28.57% |
| 1年変化 | -99.39% |
| 3年間の変化 | -99.77% |
| 5年間の変化 | -99.97% |
| IPOからの変化 | -99.88% |
最新ニュース
Seeking Alpha • Sep 21
Clovis Oncology rises on clinical supply agreement with Isotopia
Clovis Oncology (NASDAQ:CLVS) said on Wednesday it had signed a clinical supply agreement that would provide it with Isotopia’s lutetium-177 n.c.a. for use in the development of FAP-2286, fibroblast activation protein, that targets therapeutic candidate. (CLVS) has risen 4.5% before the bell. FAP-2286 is currently being developed in the Phase 1/2 study to treat patients with advanced solid tumors. The agreement covers an initial period of two years. "Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security," said Keren Moshkoviz, Deputy CEO and BD at Isotopia. FAP is highly expressed by cancer-associated fibroblasts (CAFs) which are found in the majority of cancer types, but with limited expression in healthy fibroblasts, potentially making it a suitable target across a wide range of tumors.Seeking Alpha • Sep 12
Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Clovis Oncology (NASDAQ:CLVS) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer. The company presented data from a subgroup analysis of a monotherapy comparison in the phase 3 trial called ATHENA at the European Society of Medical Oncology (ESMO) Congress 2022 in Paris. ATHENA-MONO enrolled 538 women with high-grade ovarian, fallopian tube or primary peritoneal cancer. Patients who received Rubraca as maintenance therapy showed PFS (length of time during/after therapy a patient lives with the disease without it getting worse) benefit regardless of surgical outcome, whether there was complete resection during cytoreductive surgery or not, the company said in a Sept. 11 press release. In addition, patients treated with Rubraca as maintenance therapy showed benefit among all subgroups when evaluated against response per RECIST v1.1 at any time during first-line chemotherapy. Clovis noted that in other subgroups based on baseline clinical characteristics, including FIGO stage, timing of surgery, and CA-125 levels, also showed that patients treated with Rubraca experienced a PFS benefit compared to those treated with placebo. CLVS +14.78% to $1.32 premarket Sept. 12Seeking Alpha • Aug 11
Clovis Oncology: Needs Some Encouraging Data Quickly
Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro If we look at a long-term chart of Clovis Oncology, Inc. (CLVS) (Antin Cancer Biotech Company), we see that shares topped out in 2017 and have been making sustained lower lows ever since. Suffice it to say, a lot of shareholders have been burned by this play, and if the present bearish trend continues, shares could easily test the stock's year-to-date lows of well under $1 a share. If indeed though shares swoop down to their 2022 lows in the not too distant future, the risk/reward play would be heavily skewed to the upside because of what the company still has in its locker in our opinion. Clovis Technical Chart (Stockcharts.com) Clovis Needs Capital Suffice it to say, it then would boil down to how much the company's assets are worth to a partner if indeed a third party is to enter the scene here, which now looks highly likely. Management announced on its recent quarterly earnings call that raising capital through public or private equity means is not an option at present due to the recent unsuccessful stock split. So, Clovis' current options with respect to facilitating funding seem to be to either increase the number of shares or enter into some type of licensing agreement. The reason being is that when forward-looking revenue projections and the company´s current cash-burn rate are taken into account, operations will eventually come to a grinding halt in early 2023 if no new funding is found. Rubraca Sales Are Not Growing Unfortunately, Rubraca has not performed up to expectations. This means Clovis' pipeline has literally run out of time. Rubraca sales came in at $32.1 million in the company's fiscal second quarter, which was a 6% sequential decline as well as a 13% decrease compared to the same period of 12 months prior. Covid-19 has been a clear headwind here due to fewer numbers of people going through the system. This has led to a fall-off in second-line maintenance treatment. Furthermore, recent insider selling demonstrates management's outlook on how Rubraca is expected to fare going forward, which obviously has been factored in as to when the firm will run out of money. Pipeline However, with respect to the pipeline, management was quick to point to the ongoing FAP-2286 (Lead candidate in Radionuclide therapy) LuMiere trial with respect to its recent encouraging results. When we take into account the tumor space, which is a significant area of high unmet need, along with recent evidence regarding Fap-2286's sound safety and clinical implications, this will be a trial that will be watched very closely going forward by all cohorts in this space. Then, on the Rubraca side, the ongoing TRITON3 & ATHENA studies offer the opportunity to bring to the market earlier therapy solutions for prostate and ovarian cancer patients. Regarding ovarian cancer, Clovis has plenty of indications in late stages in ATHENA-MONO & ATHENA-COMBO, where we should have updated information in this space in the latter stages of this fiscal year as well as early next year. Remember, the goal here is to widen the net so to speak with respect to patients undergoing therapy in this space. The same goes for specific prostate cancer patients in the TRITON3 trial where we should have an update over the next few months or so. Worrying Financials The question then becomes how much is this pipeline worth, notwithstanding Rubraca's U.S. and international product revenues. Remember, Clovis has well over $600 million of long-term debt on its balance sheet and continues to report negative shareholder equity. Suffice it to say, its bargaining position is not healthy, as the company will most likely have to give up more than it wishes to attract the interests of a funded third party.Recent updates
株主還元
| CLVS.Q | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 18.1% | -1.6% | -0.8% |
| 1Y | -99.4% | 34.4% | 27.1% |
業界別リターン: CLVS.Q過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: CLVS.Qは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。
価格変動
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CLVS.Qの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: CLVS.Qの 週次ボラティリティ は、過去 1 年間で39%から61%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc. 基礎のまとめ
| CLVS.Q 基礎統計学 | |
|---|---|
| 時価総額 | US$2.18m |
| 収益（TTM） | -US$251.91m |
| 売上高(TTM) | US$133.02m |
0.0x
P/Sレシオ0.0x
PER（株価収益率CLVS.Q は割高か？
公正価値と評価分析を参照収益と収入
| CLVS.Q 損益計算書（TTM） | |
|---|---|
| 収益 | US$133.02m |
| 売上原価 | US$31.59m |
| 売上総利益 | US$101.43m |
| その他の費用 | US$353.33m |
| 収益 | -US$251.91m |
直近の収益報告
Sep 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.73 |
| グロス・マージン | 76.25% |
| 純利益率 | -189.37% |
| 有利子負債／自己資本比率 | -158.0% |
CLVS.Q の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2023/07/12 20:22 |
| 終値 | 2023/07/10 00:00 |
| 収益 | 2022/09/30 |
| 年間収益 | 2021/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Clovis Oncology, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |